What is the pregnancy category of clonazepam?

Clonazepam Pregnancy Category

Clonazepam does not have a formal FDA pregnancy category because the pregnancy letter category system (A, B, C, D, X) was discontinued in 2015, but based on current FDA labeling, clonazepam carries significant pregnancy risks including potential teratogenicity and neonatal complications. 1

Current FDA Pregnancy Warnings

The FDA drug label explicitly states:

• No adequate and well-controlled studies exist in pregnant women
• Available human data on teratogenicity risk are inconclusive 1
• Animal studies demonstrate malformations (cleft palate, open eyelid, fused sternebrae, limb defects) in rabbits at all tested doses, even those comparable to human therapeutic doses 1

Specific Pregnancy Risks

Teratogenic concerns:

• Animal data show a pattern of malformations across multiple organ systems
• Human data remain insufficient to definitively establish or exclude teratogenic risk 1

Perinatal complications when used late in pregnancy or during delivery:

• Floppy infant syndrome: hypothermia, hypotonia, respiratory depression, feeding difficulties 1
• Neonatal withdrawal syndrome in infants exposed during later pregnancy stages 1
• Neonatal dependence requiring postnatal management 1

Clinical Decision Framework

If clonazepam is being considered during pregnancy:

1. Weigh maternal benefit against fetal risk - The decision requires careful assessment of whether seizure control or panic disorder management justifies potential fetal harm 1

2. Timing matters critically:

   • First trimester exposure carries theoretical teratogenic risk (organogenesis period)
   • Late third trimester/delivery exposure has documented neonatal complications 1

3. Consider alternatives first - Explore non-benzodiazepine options when feasible

4. If use is necessary:

   • Use the lowest effective dose
   • Avoid multidrug regimens when possible 2
   • Divide daily doses to avoid high peak concentrations 2
   • Plan for neonatal monitoring at delivery

Registry Enrollment

Pregnant patients taking clonazepam should enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 to contribute safety data 1

Evidence Quality Context

The research evidence shows mixed findings: one study of 43 monotherapy exposures found only 1 infant (3%) with malformations 3, and another case series of 38 pregnancies showed no orofacial anomalies or withdrawal syndromes 4. However, a population-based case-control study found no detectable teratogenic risk but acknowledged limited data 5. These reassuring human studies are small and underpowered to detect moderate increases in malformation risk - the animal data showing consistent malformations cannot be dismissed 1.

Critical Caveat

The guideline on substance use disorders specifically notes that in pregnant women with opioid use disorder requiring buprenorphine, concurrent benzodiazepine use (including clonazepam) is a relative contraindication favoring methadone instead, though buprenorphine should not be withheld if it's the only accessible option 6. This reflects serious concerns about benzodiazepine-opioid combinations in pregnancy.